7 Companies Racing to Make Sickle Cell Cures Accessible

For patients with sickle cell disease, the 2024 approval of Casgevy proved that a genetic cure was possible. But proving something works and getting it to millions of patients are two very different problems.

Casgevy requires removing a patient's stem cells, editing them in a lab, and returning them after intensive preparation. The process costs $2.2 million and demands specialized facilities most communities simply don't have. Now, a wave of companies is racing to fix those barriers.

Beam Therapeutics is refining the editing process itself with "base editing," a technique that rewrites single DNA letters without cutting the genome. Their approach recreates natural mutations that boost healthy hemoglobin levels above 60% while dropping harmful sickle hemoglobin below 40%. Early results show patients experiencing far less red blood cell sickling, and the company aims to submit for approval by the end of 2026.

Meanwhile, other teams are asking a bolder question: what if we could skip the lab entirely? Ensoma raised $53 million in 2025 to develop therapies delivered directly into the bloodstream. Their approach targets stem cells where they live, eliminating the need for cell extraction or harsh pre-treatment conditioning.

Orna Therapeutics partnered with Vertex Pharmaceuticals in early 2025 to explore a similar vision. Using circular RNA packaged in lipid nanoparticles, they're working toward gene therapies that could one day be administered like a regular infusion.

The Ripple Effect

These advances matter far beyond the lab. Sickle cell disease affects approximately 100,000 Americans and millions more globally, with the highest burden falling on communities in sub-Saharan Africa where complex, expensive treatments remain out of reach. Simpler delivery methods could mean the difference between a theoretical cure and one that actually saves lives at scale.

Each company is tackling a different piece of the puzzle. Some are making editing safer and more precise. Others are working to deliver treatment without collecting cells. Together, they're building toward a future where curing sickle cell disease doesn't require flying to specialized centers or paying millions of dollars.

The finish line isn't just a working therapy anymore—it's a working therapy that works for everyone.